Pharma companies will need to rethink business and research and development (R&D) strategies to mitigate against the global impact that will be felt from the US Government’s Inflation Reduction ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

The Inflation Reduction Act (IRA) is expected to profoundly influence the clinical development strategies of pharma companies ...

During a recent panel discussion sponsored by Purdue University, industry leaders explain how the technology is revolutionizing drug development and production ...

Coupling reactions are essential in the synthesis of pharmaceuticals, agrochemicals, and advanced materials, but traditional ...

When prescriptions are being lost to competitors with no significant clinical or cost differential, defensive strategies ... expertise development. The conservative nature of pharmaceutical ...

Pharmaceutical leaders must anticipate the changes in the regulatory landscape to stay ahead and quickly integrate compliance strategies into their long-term research and development (R&D ...

Pharmaceutical companies and their outsourcing partners must continuously adapt to new market demands, regulations, and evolving technologies. Contract development and manufacturing organisations ...

On Crowncast, Enrico Pesenti explains how cancer drug resistance forms and how advanced technologies are helping researchers ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care ...

Some people think that Chinese pharmaceutical firms are drawing notice due to their sophisticated development skills ... Buyers have developed a business strategy that enables them to import ...